Norwich, Conn. — AVS Bio has acquired Biorbyt Ltd., a global supplier of bio-reagents, antibodies, proteins and other biomaterials used in life science research.
AVS Bio, a portfolio company of Arlington Capital Partners, said the acquisition will expand its research product catalog and global distribution capabilities while adding Biorbyt’s ecommerce platform.
Founded in 2011 and headquartered in Cambridge, United Kingdom, Biorbyt offers more than 1 million products, including primary and secondary antibodies, recombinant and native proteins, ELISA kits, small molecules and molecular biology reagents. Its customers include pharmaceutical and biotechnology companies as well as academic institutions.
Biorbyt will continue operating under its existing leadership as part of the AVS Bio platform.
“With the treatment and prevention of disease becoming ever more advanced, personalized, and urgent, sophisticated biomaterials capabilities play a crucial role in their delivery,” said Jac Price, CEO of AVS Bio. “Biorbyt – with its expansive portfolio of antibodies, proteins, and reagents, and advanced ecommerce platform – marks an important step in our journey to becoming a truly diversified, leading and global biomaterials provider and will allow us to reach more customers in more geographies than ever before. We’re thrilled to welcome the Biorbyt team to the AVS Bio platform.”
Malcolm Little, a Partner at Arlington Capital Partners, said the acquisition broadens AVS Bio’s product offering while adding digital commerce capabilities and scientific and commercial expertise.
“Since our initial investment, our vision alongside AVS Bio’s leadership team has been to build it into a scaled life sciences platform with the breadth and capabilities to support customers across the research and development lifecycle,” Little said.
Dr. Tillmann Ziegert and Qun Yang, Co-Founders of Biorbyt, said the companies’ combined catalogs and ecommerce capabilities will allow them to provide researchers with a broader range of biomaterials.
AVS Bio provides critical inputs and services to the bioprocessing and biologics industries. Arlington Capital Partners is a Washington, D.C.-area private investment firm focused on government-regulated industries, including healthcare.
